FEMY Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)$-4.800.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$12.8MMicro cap

Wall Street coverage

$63.33median target· current $25.40 (+149.3%)3 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
PEG ratio
P/B
1.74
P/S (TTM)
5.40
EV/EBITDA
0.24

Profitability & growth

ROE (TTM)
-256.0%
Operating margin
-994.0%
Revenue growth YoY
24.5%
Dividend yield
Beta
-2.22
Last earnings
May 8, 2026 · Estimate $-1.80 · Reported $-1.46
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Femasys Inc

Femasys Inc. is a pioneering medical technology company focused on revolutionizing women's healthcare with its proprietary, non-surgical solutions for diagnosing and treating gynecological conditions, including uterine fibroids and contraception. By addressing significant unmet needs in women's health, Femasys is positioned to benefit from the growing demand for minimally invasive treatments, which enhance patient outcomes and improve healthcare efficiency. The company's innovative approach aims to set new standards of care, reinforcing its commitment to transforming the landscape of women's…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
3950 JOHNS CREEK COURT, SUWANEE, GA
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$12.8M
Shares outstanding$3.0M
52W high$22.20
52W low$3.77

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer